Median PFS benefit was just over 3 months in patients with EGFR-mutant NSCLC who had tumor suppressor gene co-mutations.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/nsclc-survival-benefit-seen-egfr-tki-chemo-2025a1000nlj?src=rss
Author :
Publish date : 2025-09-07 23:35:00
Copyright for syndicated content belongs to the linked Source.
